CD28 and B-cell chronic lymphocytic leukemia: Therefore, they further refined this protocol by activating CD3+ cells from CLL patients for 3–14 days with CD3/CD28 Dynabeads and IL-2 and transferred them with CLL-PBMCs into NSG mice via the retro-orbital vein [28,29,30].